type 2 diabetes
Eli Lilly and Boehringer Ingelheim are one step closer to an important label change for SGLT2 contender Jardiance.
Crossover investor Deerfield Management has joined the syndicate of Fractyl Laboratories with a $17 million addition to a Series C financing to bring it up to a total of $57 million. The startup will use the cash to continue backing clinical testing of its Revita Duodenal Mucosal Resurfacing System, which has already started an international multicenter trial and is slated to begin randomized studies in 2016.
As scientists target gastrointestinal tract procedures as a way to treat Type 2 diabetes, Fractyl Labs is forging ahead with its balloon ablation device for the disease to cash in on the trend.
Merck & Co. has encountered a few roadblocks in recent years with its diabetes drug, Januvia as safety concerns took a bite out of sales. The company has worked hard to reverse this trend, and recently unveiled data on heart safety could do its part. But now Merck could be facing another threat, and not from a regulator or competing drugmaker--but a devicemaker.
Researchers at the University of Southampton have developed a small molecule which they refer to as "Compound 14" that deceives cells into thinking they have run out of energy--spurring on glucose uptake and increasing metabolism.
Fractyl Laboratories has started a sizable clinical trial to test its noninvasive duodenal resurfacing technology as a treatment for insulin resistance in Type 2 diabetes patients. The news comes after the startup garnered a $40 million Series C round from investors including Mithril Capital Management last fall.
Ethicon, the Johnson & Johnson unit devoted to surgical tools, is moving to defend its bariatric surgery territory as a slew of noninvasive medical devices to treat obesity line up to gain approval in the U.S. It will spend $3.2 million on more than 20 clinical trials to examine how early surgical intervention can be used to improve conditions such as obesity and Type 2 diabetes.
Following the theory that Type 2 diabetes is triggered by inflammation, a group of researchers at the German Cancer Research Center concluded that turning off the enzyme Kit prevented a cascade of metabolically linked pathogenic processes.
An international group of investigators led by a scientist at Cedars-Sinai has identified a genetic mutation that protects people from Type 2 diabetes. And they say it makes for a good target for drug developers.
An investigator at Columbia University Medical Center with close ties to Tarrytown, NY-based Armgo Pharma has published new animal data to back up the promise of their clinical-stage diabetes drug Rycal.